Icatibant Aguettant (Icatibant)

Icatibant blocks the bradykinin B2 receptor, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. This inhibition stops the cascade that leads to the rapid swelling seen in hereditary angioedema attacks.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. The prescriber will decide the exact amount and frequency appropriate for each individual case.

Safety data for icatibant during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative for HAE attacks is C1‑esterase inhibitor replacement therapy. Icatibant acts by blocking bradykinin receptors, offering a rapid sub‑cutaneous option, whereas C1‑esterase inhibitors replace the deficient protein and are administered intravenously. Choice depends on clinical response, patient preference and accessibility.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after appropriate instruction, by the patient or caregiver using the supplied pre‑filled syringe.

Serious adverse reactions include anaphylaxis, severe hypotension, and unexpected angioedema at sites other than the treated area. If any of these occur, immediate medical attention is required and the medication should be discontinued.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Patients with a history of severe allergic reactions to bradykinin antagonists should avoid its use.